Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
40.68 USD -0.32% Intraday chart for Ionis Pharmaceuticals, Inc. -2.54% -19.59%
Apr. 11 North American Morning Briefing : Stock Futures -2- DJ
Apr. 10 Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform MT

Business Summary

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Number of employees: 927

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Therapeutic Medicines
100.0 %
587 100.0 % 788 100.0 % +34.10%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
587 100.0 % 788 100.0 % +34.10%

Managers

Managers TitleAgeSince
D. Walke FOU
 Founder 58 12-06-30
Brett Monia FOU
 Founder 62 89-01-09
Elizabeth Hougen DFI
 Director of Finance/CFO 62 00-04-30
Eugene Schneider CTO
 Chief Tech/Sci/R&D Officer - -
Sanjay Bhanot CTO
 Chief Tech/Sci/R&D Officer - 99-12-31
Joel Ekstorm CTO
 Chief Tech/Sci/R&D Officer - -
Tracy Berns CMP
 Compliance Officer - -
C. Bennett CTO
 Chief Tech/Sci/R&D Officer 67 88-12-31
B. Parshall BRD
 Director/Board Member 69 91-10-31
Dave Ecker PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Joseph Loscalzo CHM
 Chairman 72 14-02-02
Brett Monia FOU
 Founder 62 89-01-09
Joan Herman BRD
 Director/Board Member 70 19-06-09
Joseph Klein BRD
 Director/Board Member 62 05-12-12
B. Parshall BRD
 Director/Board Member 69 91-10-31
Joseph Wender BRD
 Director/Board Member 79 93-12-31
Spencer R. Berthelsen BRD
 Director/Board Member 71 02-04-30
Michael Hayden BRD
 Director/Board Member 72 18-09-23
Allene Diaz BRD
 Director/Board Member 59 21-06-02
Michael Yang BRD
 Director/Board Member 62 Dec. 13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 145,751,797 144,488,756 ( 99.13 %) 0 99.13 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.77 %
21,520,872 14.77 % 933 M $
Vanguard Fiduciary Trust Co.
9.745 %
14,203,481 9.745 % 616 M $
T. Rowe Price Investment Management, Inc.
9.057 %
13,201,453 9.057 % 572 M $
Bellevue Asset Management AG
5.979 %
8,713,987 5.979 % 378 M $
BB BIOTECH AG
5.894 %
8,590,000 5.894 % 372 M $
BlackRock Advisors LLC
5.711 %
8,324,093 5.711 % 361 M $
Berkshire Asset Management LLC
3.233 %
4,711,660 3.233 % 204 M $
Wellington Management Co. LLP
3.168 %
4,616,978 3.168 % 200 M $
T. Rowe Price International Ltd.
2.919 %
4,255,074 2.919 % 184 M $
STATE STREET CORPORATION
2.750 %
4,008,797 2.750 % 174 M $

Company contact information

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court

92010, Carlsbad

+760 931 9200

http://www.ionispharm.com
address Ionis Pharmaceuticals, Inc.(IONS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
40.68 USD
Average target price
58.13 USD
Spread / Average Target
+42.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IONIS PHARMACEUTICALS, INC. Stock Ionis Pharmaceuticals, Inc.
-19.59% 5.95B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IONS Stock
  4. Company Ionis Pharmaceuticals, Inc.